[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1456347A4 - Antibodies that immunospecifically bind to blys - Google Patents

Antibodies that immunospecifically bind to blys

Info

Publication number
EP1456347A4
EP1456347A4 EP02802570A EP02802570A EP1456347A4 EP 1456347 A4 EP1456347 A4 EP 1456347A4 EP 02802570 A EP02802570 A EP 02802570A EP 02802570 A EP02802570 A EP 02802570A EP 1456347 A4 EP1456347 A4 EP 1456347A4
Authority
EP
European Patent Office
Prior art keywords
blys
antibodies
immunospecifically bind
immunospecifically
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02802570A
Other languages
German (de)
French (fr)
Other versions
EP1456347A2 (en
Inventor
Steven M Ruben
Steven C Barash
Gil H Choi
Tristan J Vaughan
David Hilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1456347A2 publication Critical patent/EP1456347A2/en
Publication of EP1456347A4 publication Critical patent/EP1456347A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02802570A 2001-11-16 2002-11-14 Antibodies that immunospecifically bind to blys Withdrawn EP1456347A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33146901P 2001-11-16 2001-11-16
US331469P 2001-11-16
US34081701P 2001-12-19 2001-12-19
US340817P 2001-12-19
PCT/US2002/036496 WO2003055979A2 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Publications (2)

Publication Number Publication Date
EP1456347A2 EP1456347A2 (en) 2004-09-15
EP1456347A4 true EP1456347A4 (en) 2006-08-02

Family

ID=26987779

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02802570A Withdrawn EP1456347A4 (en) 2001-11-16 2002-11-14 Antibodies that immunospecifically bind to blys

Country Status (4)

Country Link
EP (1) EP1456347A4 (en)
AU (1) AU2002364954A1 (en)
CA (1) CA2467521A1 (en)
WO (1) WO2003055979A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
DK1146892T3 (en) 1999-01-25 2003-11-24 Apoxis Sa BAFF, its inhibitors and their use in modulating the B cell response
HU230583B1 (en) 1999-08-17 2017-02-28 Biogen Idec Ma Inc. Uses of baff-receptor (bcma) as an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
KR101287395B1 (en) 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to BLyS
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
JP2007536896A (en) 2003-06-05 2007-12-20 ジェネンテック・インコーポレーテッド BLYS antagonists and their uses
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
CN101921340A (en) 2004-03-31 2010-12-22 佳能株式会社 Protein
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1826218B1 (en) * 2004-08-31 2014-01-01 Kowa Company, Ltd. Antihuman baff antibody
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
CN101678106B (en) 2007-03-27 2013-06-05 津莫吉尼蒂克斯公司 Combination of Blys inhibition and/or APRIL inhibition and immunnosuppressants for treatment of autoimmune disease
AR068767A1 (en) 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
EP2233149B1 (en) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN103421113B (en) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 Anti- BLyS antibody
CN104045713B (en) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 The monoclonal antibody of anti-Blys a kind of and pharmaceutical composition containing the antibody
US20210347873A1 (en) * 2016-07-06 2021-11-11 Shanghai Pharmaexplorer Co., Ltd. Blys antibody, preparation method therefor and application thereof
EP3576790A4 (en) 2017-02-01 2020-12-23 Yale University Treatment of diuretic resistance
EA202091640A1 (en) 2018-01-05 2020-10-26 Корвидиа Терапьютикс, Инк. METHODS FOR TREATMENT OF IL-6-MEDIATED INFLAMMATION WITHOUT IMMUNODEPRESSION

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GROSS J A ET AL: "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 404, 27 April 2000 (2000-04-27), pages 995 - 999, XP002140939, ISSN: 0028-0836 *
GROSS J A; ET AL: "TACI-IG Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLYS", IMMUNITY, vol. 15, August 2001 (2001-08-01), pages 289 - 302, XP003008630 *
SCHNEIDER P ET AL: "BAFF, A NOVEL LIGAND OF THE TUMOR NECROSIS FACTOR FAMILY, STIMULATES B CELL GROWTH", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747 - 1756, XP000915409, ISSN: 0022-1007 *
SHU H-B ET AL: "TALL-1 IS A NOVEL MEMBER OF THE TNF FAMILY THAT IS DOWN-REGULATED BY MITOGENS", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 65, no. 5, May 1999 (1999-05-01), pages 680 - 683, XP000939092, ISSN: 0741-5400 *
WU Y; ET AL: "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 45, 10 November 2000 (2000-11-10), pages 35478 - 35485, XP002367757 *
ZHOU T ET AL: "THERAPEUTIC POTENTIAL OF ANTAGONIZING BLYS FOR CHRONIC LYMPHOCYTIC LEUKEMIA", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 98, no. 11, PART 1, 16 November 2001 (2001-11-16), pages 808A, XP009041133, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2003055979A3 (en) 2003-12-18
WO2003055979A2 (en) 2003-07-10
AU2002364954A8 (en) 2003-07-15
EP1456347A2 (en) 2004-09-15
CA2467521A1 (en) 2003-07-10
AU2002364954A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
AU2002364954A8 (en) Antibodies that immunospecifically bind to blys
CY2012003I1 (en) ANTIBODIES THAT BIND IMMUNOSPECIFICALLY TO BLYS
EP1465925A4 (en) Antibodies that immunospecifically bind to trail receptors
HK1075470A1 (en) Antibodies that immunospecifically bind to trail receptors
EP1572874A3 (en) Antibodies that immunospecifically bind to trail receptors
IL213564A0 (en) Antibodies to vla-1
IL235116A0 (en) Antibodies to opgl
GB0417384D0 (en) Antibodies to c-met
HK1096873A1 (en) Peptides and compounds that bind to thrombopoietin receptors
AU2002359659A8 (en) Cross reference to related application
AU2003234706A8 (en) Antibodies that specifically bind to tl5
AU2003218456A8 (en) Antibodies that specifically bind to gmad
AU2003256299A8 (en) Antibodies that specifically bind to reg iv
AU2003240822A8 (en) Antibodies that specifically bind to neurokinin b
EP1633316A4 (en) Antibodies that immunospecifically bind to trail receptors
AU2003302822A8 (en) Antibodies to treat cancer
AU2002352676A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2003288809A8 (en) Peptides that bind of the vegfr-2
AU2003259835A8 (en) Antibodies that immunospecifically bind to trail receptors
EP1339426A4 (en) Antibodies that immunospecifically bind to trail receptors
AU2003228483A8 (en) Antibodies that specifically bind to tr2

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 5/12 B

Ipc: 7C 12N 15/86 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 07H 21/04 A

A4 Supplementary search report drawn up and despatched

Effective date: 20060704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20060628BHEP

Ipc: A61P 37/06 20060101ALI20060628BHEP

Ipc: A61K 39/395 20060101ALI20060628BHEP

Ipc: C07K 16/28 20060101ALI20060628BHEP

Ipc: C12N 5/10 20060101ALI20060628BHEP

Ipc: C12N 15/13 20060101ALI20060628BHEP

Ipc: C12N 5/12 20060101ALI20060628BHEP

Ipc: C12N 15/86 20060101ALI20060628BHEP

Ipc: C12N 15/85 20060101ALI20060628BHEP

Ipc: C07H 21/04 20060101AFI20040921BHEP

17Q First examination report despatched

Effective date: 20070710

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080122